Novo Nordisk Guidance at Risk After CEO News -- Market Talk

Dow Jones

May 20, 2025

0743 GMT - Novo Nordisk's CEO departure suggests another profit warning is highly possible, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. Consensus estimates for sales of the Danish pharma giant's Ozempic diabetes drug this year look too high, as new prescriptions have now turned negative, the analysts say. Meanwhile, Intron's expectations that sales of the Wegovy obesity drug will reach an inflection point thanks to a deal with CVS Health and the anticipated end of sales of compounded versions is likely a best-case scenario, the analysts say. "Furthermore, following Friday's CEO news, we believe there is further risk to 2025 guidance," Intron says. Novo Nordisk earlier this month cut its full-year guidance and on Friday said CEO Lars Fruergaard Jorgensen would leave the company. Shares rise 1.9%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 20, 2025 03:43 ET (07:43 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2536857695"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536857695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536857695?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 15:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536857695","market":"hk","top_or_hot":-1,"title":"Novo Nordisk Guidance at Risk After CEO News -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0743 GMT - Novo Nordisk's CEO departure suggests another profit warning is highly possible, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. Consensus estimates for sales of the Danish pharma giant's Ozempic diabetes drug this year look too high, as new prescriptions have now turned negative, the analysts say. Meanwhile, Intron's expectations that sales of the Wegovy obesity drug will reach an inflection point thanks to a deal with CVS Health and the anticipated end of sales of compounded versions is likely a best-case scenario, the analysts say. \"Furthermore, following Friday's CEO news, we believe there is further risk to 2025 guidance,\" Intron says. Novo Nordisk earlier this month cut its full-year guidance and on Friday said CEO Lars Fruergaard Jorgensen would leave the company. Shares rise 1.9%. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 20, 2025 03:43 ET (07:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Guidance at Risk After CEO News -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Guidance at Risk After CEO News -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-20 15:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0743 GMT - Novo Nordisk's CEO departure suggests another profit warning is highly possible, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. Consensus estimates for sales of the Danish pharma giant's Ozempic diabetes drug this year look too high, as new prescriptions have now turned negative, the analysts say. Meanwhile, Intron's expectations that sales of the Wegovy obesity drug will reach an inflection point thanks to a deal with CVS Health and the anticipated end of sales of compounded versions is likely a best-case scenario, the analysts say. \"Furthermore, following Friday's CEO news, we believe there is further risk to 2025 guidance,\" Intron says. Novo Nordisk earlier this month cut its full-year guidance and on Friday said CEO Lars Fruergaard Jorgensen would leave the company. Shares rise 1.9%. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 20, 2025 03:43 ET (07:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2536857695","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536857695","pubTimestamp":1747726980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0743 GMT - Novo Nordisk's CEO departure suggests another profit warning is highly possible, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. Consensus estimates for sales of the Danish pharma giant's Ozempic diabetes drug this year look too high, as new prescriptions have now turned negative, the analysts say. Meanwhile, Intron's expectations that sales of the Wegovy obesity drug will reach an inflection point thanks to a deal with CVS Health and the anticipated end of sales of compounded versions is likely a best-case scenario, the analysts say. \"Furthermore, following Friday's CEO news, we believe there is further risk to 2025 guidance,\" Intron says. Novo Nordisk earlier this month cut its full-year guidance and on Friday said CEO Lars Fruergaard Jorgensen would leave the company. Shares rise 1.9%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4532":"文艺复兴科技持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4599":"减肥药","NVO":"诺和诺德","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC"},"translate_title":"首席执行官新闻发布后诺和诺德指引面临风险——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"0743 GMT - Novo Nordisk's CEO departure suggests another profit warning is highly possible, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. Consensus estimates for sales of the Danish pharma giant's Ozempic diabetes drug this year look too high, as new prescriptions have now turned negative, the analysts say. Meanwhile, Intron's expectations that sales of the Wegovy obesity drug will reach an inflection point thanks to a deal with CVS Health and the anticipated end of sales of compounded versions is likely a best-case scenario, the analysts say. \"Furthermore, following Friday's CEO news, we believe there is further risk to 2025 guidance,\" Intron says. Novo Nordisk earlier this month cut its full-year guidance and on Friday said CEO Lars Fruergaard Jorgensen would leave the company. Shares rise 1.9%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2025 03:43 ET (07:43 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}